​

Supernus Pharmaceuticals (SUPN) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Supernus Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$718.95M

Latest Revenue (Q)

$192.10B

Main Segment (Y)

Product

Supernus Pharmaceuticals Revenue by Period

Supernus Pharmaceuticals Revenue by Year

DateRevenueChange
2025-12-31$718.95M8.63%
2024-12-31$661.82M8.94%
2023-12-31$607.52M-8.95%
2022-12-31$667.24M15.09%
2021-12-31$579.77M11.41%
2020-12-31$520.40M32.50%
2019-12-31$392.75M-3.95%
2018-12-31$408.90M35.29%
2017-12-31$302.24M40.57%
2016-12-31$215.00M48.87%
2015-12-31$144.43M18.34%
2014-12-31$122.05M915.43%
2013-12-31$12.02M712.09%
2012-12-31$1.48M84.31%
2011-12-31$803.00K657.55%
2010-12-31$106.00K-99.72%
2009-12-31$37.92M326.65%
2008-12-31$8.89M109.97%
2007-12-31$4.23M-

Supernus Pharmaceuticals generated $718.95M in revenue during NA 2025, up 8.63% compared to the previous quarter, and up 138.15% compared to the same period a year ago.

Supernus Pharmaceuticals Revenue by Quarter

DateRevenueChange
2025-09-30$192.10B116007.29%
2025-06-30$165.45M10.43%
2025-03-31$149.82M-13.97%
2024-12-31$174.16M-0.87%
2024-09-30$175.69M4.37%
2024-06-30$168.32M17.18%
2024-03-31$143.64M-12.58%
2023-12-31$164.31M6.78%
2023-09-30$153.88M13.51%
2023-06-30$135.56M-11.84%
2023-03-31$153.76M-8.11%
2022-12-31$167.33M-5.65%
2022-09-30$177.35M4.29%
2022-06-30$170.05M11.50%
2022-03-31$152.51M-4.11%
2021-12-31$159.05M7.13%
2021-09-30$148.46M5.05%
2021-06-30$141.33M7.94%
2021-03-31$130.93M-8.79%
2020-12-31$143.56M-7.46%
2020-09-30$155.13M22.41%
2020-06-30$126.73M33.43%
2020-03-31$94.98M-5.45%
2019-12-31$100.45M-1.66%
2019-09-30$102.14M-2.44%
2019-06-30$104.69M22.49%
2019-03-31$85.47M-26.27%
2018-12-31$115.93M12.56%
2018-09-30$103.00M3.47%
2018-06-30$99.54M10.07%
2018-03-31$90.43M2.25%
2017-12-31$88.44M10.00%
2017-09-30$80.40M6.03%
2017-06-30$75.83M31.70%
2017-03-31$57.58M-7.69%
2016-12-31$62.37M9.79%
2016-09-30$56.81M12.67%
2016-06-30$50.42M17.05%
2016-03-31$43.08M0.98%
2015-12-31$42.66M10.55%
2015-09-30$38.59M10.08%
2015-06-30$35.05M24.59%
2015-03-31$28.13M-8.66%
2014-12-31$30.80M-41.32%
2014-09-30$52.49M76.88%
2014-06-30$29.68M226.78%
2014-03-31$9.08M-12.13%
2013-12-31$10.34M722.20%
2013-09-30$1.26M347.33%
2013-06-30$281.00K91.16%
2013-03-31$147.00K-86.50%
2012-12-31$1.09M1096.70%
2012-09-30$91.00K-
2012-06-30$91.00K-56.25%
2012-03-31$208.00K-102.11%
2011-12-31$-9.85M-89600.00%
2011-09-30$11.00K-98.53%
2011-06-30$750.00K100.00%
2011-03-31--100.00%
2010-12-31$-8.63M67.83%
2009-12-31$-5.14M-

Supernus Pharmaceuticals generated $192.10B in revenue during Q3 2025, up 116007.29% compared to the previous quarter, and up 114126.24% compared to the same period a year ago.

Supernus Pharmaceuticals Revenue Breakdown

Supernus Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
Oxtellar X R$40.70M$99.46M$113.40M$115.34M$110.71M
APOKYN$47.77M$73.93M$75.08M$75.31M$99.23M
Product$626.54M$637.70M$573.93M$649.43M$567.50M
Qelbree$304.65M$241.27M$140.19M$61.32M$9.88M
Royalty, License And Other Revenue$39.42M$24.12M---
Trokendi Xr$42.42M$63.20M$94.34M$261.22M$304.82M
Collaboration Revenue$53.00M----
GOCOVRI$146.82M$130.82M$119.64M$104.42M$9.78M
Manufactured Product, Other$26.91M$29.01M$31.28M$31.82M-
Royalty--$33.59M$17.81M$12.27M
MYOBLOC----$19.51M
Osomolex ER----$188.00K
XADAGO----$13.39M

Supernus Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (47.17%), Qelbree (22.94%), GOCOVRI (11.05%), Collaboration Revenue (3.99%), APOKYN (3.60%), Trokendi Xr (3.19%), Oxtellar X R (3.06%), Royalty, License And Other Revenue (2.97%), and Manufactured Product, Other (2.03%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Manufactured Product, Other$4.77M$7.03M$6.53M$8.58M$14.50M$7.30M$7.21M$8.27M$7.25M$7.88M$7.87M$8.25M$8.13M$7.65M$7.78M-----
GOCOVRI$38.63M$40.85M$36.66M$30.69M$68.61M$35.66M$26.56M$31.99M$32.89M$28.75M$26.01M$29.24M$27.88M$24.70M$22.60M-----
Collaboration Revenue$32.83M$20.16M------------------
APOKYN$9.59M$10.39M$12.82M$14.98M$37.41M$19.87M$16.65M$18.76M$21.51M$17.61M$17.21M$18.15M$18.26M$20.45M$18.45M$25.89M$24.63M$26.98M$21.73M$31.21M
Product$158.01M$168.54M$158.00M$141.99M$328.93M$170.30M$138.46M$156.02M$149.00M$128.34M$140.57M$163.78M$172.72M$165.46M$147.46M$154.96M$145.53M$138.63M$128.38M$140.74M
Oxtellar X R$6.85M$12.02M$11.64M$10.20M$42.72M$29.80M$26.94M$31.05M$29.64M$23.80M$28.91M$27.34M$30.53M$29.96M$27.52M$28.59M$29.73M$25.02M$27.37M$22.74M
Qelbree$80.95M$81.42M$77.55M$64.75M$133.81M$62.36M$45.10M$46.35M$37.08M$30.98M$25.78M$23.61M$18.33M$11.10M$8.28M$7.19M$2.37M$315.00K--
Royalty, License And Other Revenue$20.73M$3.40M$7.46M$7.84M$18.73M$5.39M--------------
Trokendi Xr$8.38M$10.04M$11.19M$12.80M$31.89M$15.32M$15.99M$19.60M$20.63M$19.32M$34.79M$57.19M$69.60M$71.60M$62.83M$73.29M$80.94M$78.78M$71.82M$78.51M
Royalty And License------$5.18M-------------
Royalty-------$8.30M$4.88M$7.23M$13.19M$3.54M$4.63M$4.59M$5.04M$4.09M$2.93M$2.70M$2.55M$2.81M
XADAGO---------------$4.00M$3.28M$2.89M$3.22M$3.81M
MYOBLOC---------------$6.04M$4.60M$4.64M$4.24M$4.47M

Supernus Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product (43.80%), Qelbree (22.44%), GOCOVRI (10.71%), Collaboration Revenue (9.10%), Royalty, License And Other Revenue (5.75%), APOKYN (2.66%), Trokendi Xr (2.32%), Oxtellar X R (1.90%), and Manufactured Product, Other (1.32%).

Supernus Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BHCBausch Health Companies$10.16B$912.00M
PRGOPerrigo$4.25B$1.04B
AMRXAmneal Pharmaceuticals$3.02B$784.51M
LNTHLantheus$1.54B$384.01M
INDVIndivior Pharmaceuticals$1.24B$314.00M
HCMHUTCHMED (China)$838.00M$152.84M
SUPNSupernus Pharmaceuticals$718.95M$192.10B
GRALGRAIL$147.17M$36.19M
XENEXenon Pharmaceuticals$7.50M-
CGONCG Oncology$4.04M$1.67M
CNTACentessa Pharmaceuticals--

SUPN Revenue FAQ

What is Supernus Pharmaceuticals’s yearly revenue?

Supernus Pharmaceuticals's yearly revenue for 2025 was $718.95M, representing an increase of 8.63% compared to 2024. The company's yearly revenue for 2024 was $661.82M, representing an increase of 8.94% compared to 2023. SUPN's yearly revenue for 2023 was $607.52M, representing a decrease of -8.95% compared to 2022.

What is Supernus Pharmaceuticals’s quarterly revenue?

Supernus Pharmaceuticals's quarterly revenue for Q3 2025 was $192.1B, a 116007.29% increase from the previous quarter (Q2 2025), and a 109242.65% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $165.45M, a 10.43% increase from the previous quarter (Q1 2025), and a -1.71% decrease year-over-year (Q2 2024). SUPN's quarterly revenue for Q1 2025 was $149.82M, a -13.97% decrease from the previous quarter (Q4 2024), and a 4.30% increase year-over-year (Q1 2024).

What is Supernus Pharmaceuticals’s revenue growth rate?

Supernus Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 18.34%, and for the last 5 years (2021-2025) was 24.01%.

What are Supernus Pharmaceuticals’s revenue streams?

Supernus Pharmaceuticals's revenue streams in c 25 are Oxtellar X R, APOKYN, Product, Qelbree, Royalty, License And Other Revenue, Trokendi Xr, Collaboration Revenue, GOCOVRI, and Manufactured Product, Other. Oxtellar X R generated $40.7M in revenue, accounting 3.06% of the company's total revenue, down -59.08% year-over-year. APOKYN generated $47.77M in revenue, accounting 3.60% of the company's total revenue, down -35.38% year-over-year. Product generated $626.54M in revenue, accounting 47.17% of the company's total revenue, down -1.75% year-over-year. Qelbree generated $304.65M in revenue, accounting 22.94% of the company's total revenue, up 26.27% year-over-year. Royalty, License And Other Revenue generated $39.42M in revenue, accounting 2.97% of the company's total revenue, up 63.43% year-over-year. Trokendi Xr generated $42.42M in revenue, accounting 3.19% of the company's total revenue, down -32.88% year-over-year. Collaboration Revenue generated $53M in revenue, accounting 3.99% of the company's total revenue GOCOVRI generated $146.82M in revenue, accounting 11.05% of the company's total revenue, up 12.23% year-over-year. Manufactured Product, Other generated $26.91M in revenue, accounting 2.03% of the company's total revenue, down -7.23% year-over-year.

What is Supernus Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Supernus Pharmaceuticals was Product. This segment made a revenue of $626.54M, representing 47.17% of the company's total revenue.